In accordance with the earlier findings that MYC-induced sumoylation is a therapeutic Achilles’ heel in B-cell lymphomas or that SAE1/UBA2 silencing causes synthetic lethality in MYC-amplified breast cancers, multiple MYC-expressing cancer cell lines are exceptionally hypersensitive to ML-792 [172,199,200]. The gene discussed is MYC; the disease is breast carcinoma.